Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time. The conference is being held at the St. Regis Hotel in New York. A live webcast can be accessed by visiting the investors section of the Company’s

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 26, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor

Download PDF Private Placement Provides Gross Proceeds of Approximately $17 Million;Amended Term Loan to Provide up to $10 Million in Funding CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 18, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 13, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors. The private placement will consist of 17,642,482 units, at a price of $0.965 per unit, for gross proceeds of approximately $17 million,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 10, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016. “We achieved several important goals in the first quarter critical to advancing the corporate strategy we outlined early in 2015. This includes the submission and validation of an MAA filing in Europe for tivozanib in front-line RCC by

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 2, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company’s potent inhibitory antibody specific to Notch 3. These patent applications are the second set of applications related to AV-353 and

Download PDF CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–Mar. 21, 2016– AVEO Oncology (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, today announced an exclusive collaboration and license agreement in which AVEO has granted CANbridge Life Sciences worldwide rights, excluding the United States, Canada, and Mexico, to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. CANbridge plans to

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update. “Over the course of 2015, AVEO has streamlined its organization and taken a fresh strategic direction to create increased shareholder value. In 2016, we are squarely focused on furthering the execution of this strategy,”